There is an increasing interest in the use of spore-forming Bacillus spp. as probiotic ingredients on the market. However, probiotics Bacillus species are insu cient, and more safe Bacillus species were required. In the study, traditional fermented foods and soil samples were collected from all over the country in China, and 506 Bacillus were selected from 109 samples. Using the optimized procedure, we screened 9 strains, which successfully passed the acid, alkali, bile salt and trypsin resistance test. Drug sensitivity test results showed that three Bacillus out of the 9 isolates exhibited antibiotic sensitivity to more than 29 antibiotics. The 3 strains sensitive to antibiotics were identi ed by 16S ribosomal RNA, recA and gyrB gene analysis, two isolates (38327 and 38328) belong to the specie Lysinibacillus capsici and one isolate (37326) belong to Bacillus halotolerans. Moreover, the 3 strains were con rmed safe through animal experiments. Finally, L. capsici 38327 and 38328 showed the protection in Salmonella typhimurium infection mouse model, which manifested in slowing down weight loss, reducing bacterial load, improving antioxidant capacity. Altogether, our data demonstrate selected L. capsici strains can be used novel probiotics for intestinal health.
There is an increasing interest in the use of spore-forming Bacillus spp. as probiotic ingredients on the market. However, probiotics Bacillus species are insufficient, and more safe Bacillus species were required. In the study, traditional fermented foods and soil samples were collected from all over the country in China, and 506 Bacillus were selected from 109 samples. Using the optimized procedure, we screened 9 strains, which successfully passed the acid, alkali, bile salt and trypsin resistance test. Drug sensitivity test results showed that three Bacillus out of the 9 isolates exhibited antibiotic sensitivity to more than 29 antibiotics. The 3 strains sensitive to antibiotics were identified by 16S ribosomal RNA, recA and gyrB gene analysis, two isolates (38327 and 38328) belong to the specie Lysinibacillus capsici and one isolate (37326) belong to Bacillus halotolerans. Moreover, the 3 strains were confirmed safe through animal experiments. Finally, L. capsici 38327 and 38328 showed the protection in Salmonella infection mouse model, which manifested in slowing down weight loss, reducing bacterial load, improving antioxidant capacity. Altogether, our data demonstrate selected L. capsici strains can be used novel probiotics for intestinal health.
Lysinibacillus sp. is a spore-forming gram-positive bacterium showing excellent adaptive capacity to environment, convenience to storage and antimicrobial properties. Thus, it has appeared a huge potential as probiotics in application, but related studies remain limited. This study was conducted to determine the effects of supplementary Lysinibacillus (L.) macroides 38328 in drinking water on antioxidant capacity and avian influenza virus vaccine immune response of laying hens. Hereon, layers were fed with drinking water with or without supplementary L. macroides 38328 at the dose of 7×109 colony-forming units per milliliter (CFU/mL). The results showed that supplementation with L. macroides 38328 significantly improved the layers’ productive performance while enhancing their antioxidant capacity and immunity. According to the testing results, the rise of serum T-AOC and the downtrend of serum MDA were significant (P < 0.05), while the uptrend of serum SOD concentration was extremely significant (P < 0.01). The bacillus additive also markedly increased the hens’ Stimulation Index and the AIV antibody titer to a trivalent inactivated H5 + H7 vaccine (P < 0.05). Meanwhile, significant improvements (P < 0.05) of productive performance indexes were also noted in treated birds. In conclusion, with its oral safety for laying hens verified, supplementary L. macroides 38328 had positive effects on layers’ heath condition and productivity, indicating great applied potential as a new probiotics strain.
There is an increasing interest in the use of spore-forming Bacillus spp. as probiotic ingredients on the market. However, probiotics Bacillus species are insufficient, and more safe Bacillus species were required. In the study, traditional fermented foods and soil samples were collected from all over the country in China, and 506 Bacillus were selected from 109 samples. Using the optimized procedure, we screened 9 strains, which successfully passed the acid, alkali, bile salt and trypsin resistance test. Drug sensitivity test results showed that three Bacillus out of the 9 isolates exhibited antibiotic sensitivity to more than 29 antibiotics. The 3 strains sensitive to antibiotics were identified by 16S ribosomal RNA, recA and gyrB gene analysis, two isolates (38327 and 38328) belong to the specie Lysinibacillus capsici and one isolate (37326) belong to Bacillus halotolerans. Moreover, the 3 strains were confirmed safe through animal experiments. Finally, L. capsici 38327 and 38328 showed the protection in Salmonella typhimurium infection mouse model, which manifested in slowing down weight loss, reducing bacterial load, improving antioxidant capacity. Altogether, our data demonstrate selected L. capsici strains can be used novel probiotics for intestinal health.
Enterococci resistance is increasing sharply, which poses a serious threat to public health. Rhamnolipids are a kind of amphiphilic compound used for its bioactivities, while the combination of nontraditional drugs to restore linezolid activity is an attractive strategy to treat infections caused by these pathogens. This study aimed to investigate the activity of linezolid in combination with the rhamnolipids againstEnterococcus faecium. Here, we determined that the rhamnolipids could enhance the efficacy of linezolid against enterococci infections by a checkerboard MIC assay, a time-kill assay, a combined disk test, anti-biofilm assay, molecular simulation dynamics, and mouse infection models. We identified that the combination of rhamnolipids and linezolid restored the linezolid sensitivity. Anti-biofilm experiments show that our new scheme can effectively inhibit biofilm generation. The mouse infection model demonstrated that the combination therapy significantly reduced the bacterial load in the feces, colons and kidneys following subcutaneous administration. This study showed that rhamnolipids could play a synergistic role with linezolid against Enterococcus. Our combined agents could be appealing candidates for developing new combinatorial agents to restore antibiotic efficacy in the treatment of linezolid-resistantEnterococcusinfections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.